BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction
Clear and well referenced
Methods
Is there a frozen stability of biomarkers? Results "and there was a very high correlation between hypertension and the intake of heart medications" is this relevant? Table 1 . I woudl remove some parameters, keeping only those which are in the following tables
Conclusion
The key point is the following: do we really need an early biomarker for mesothelioma? "In a recent study, we were able to demonstrate that a combination of mesothelin and calretinin was able to improve the performance of mesothelin alone (unpublished results)" This is a relevant point which can not be simply described
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GENERAL COMMENTS
This is an important study showing that mesothelin and calretinin have high specificities in a cohort of cancer-free elderly men, and that calretinin might be a useful adjunct to mesothelin for the early detection of mesothelioma, with an increase of the specificity to 99.1% (95% CI 97.9 -99.7%) for this marker panel. Moroever, the Authors correctly pointed out that mesothelin was strongly affected by renal dysfunction and at a lower degree by hypertension. Calretinin positivity was also affected by renal dysfunction -but to a lesser extent -and showed no association with hypertension.
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GENERAL COMMENTS
This study from Casjens and colleagues aims to determine plasma levels of the two malignant mesothelioma markers mesothelin and calretinin in a population of cancer-free individuals in order to identify confounding factors influencing their concentrations. Study information on potential influencing parameters was gathered from initial and follow-up questionnaires from a prospective populationbased cohort of 579 elderly men. Variables such as age and hypertension were significantly associated with an increase in mesothelin levels, while no influence of these factors could be found on calretinin. Overall specificity for mesothelin and calretinin were each close to 95%, and a combination of both markers improved specificity above 99%, supporting the use of both markers in the detection of malignant mesothelioma. This is a well-conducted, very informative population-based study which provides support for the combined use of the two blood-based markers mesothelin and calretinin in order to prevent the detection of false positive for malignant mesothelioma in elderly population afflicted of confounding factors such as hypertension and diabetes. A few additional details regarding the study population and methodology employed should be provided. Table 2 : Was the study population only composed of Caucasian individuals? If not, detailed information about race/ethnicity and percentages of total study population should be provided here.
1-
2-In "Strengths and limitations of this study", page 4: Because the present study included only men, it is not possible to determine whether gender differences exist regarding the association between calretinin, mesothelin, and the potential confounding factors investigated. This should be indicated here as a limitation of the study.
3-Introduction, page 5, lines 30-35: Only one reference describing on the use of calretinin as an immunohistochemical marker for mesothelioma is provided here. Because the authors used calretinin as a blood-based marker in this study, the reference describing the methodology employed (reference 11) should be provided here.
4-Page 7, first paragraph: Interassay and intraassay coefficients of variation should be provided for both the mesothelin and calretinin blood-based assays.
5-Page 7, line 16: It is mentioned that the cut-off point for positive calretinin values was set at 1.0 ng/mL and above. In a previous study from these authors describing development of the blood-based assay for calretinin, the median calretinin values in patients with malignant mesothelioma was found to be 0.84 ng/mL. The authors should explain why they decided to use a higher cut-off value in the present study.
6-Page 12, line 18: Please correct the typo at "non-hypertensive" High stability of mesothelin and calretinin in plasma/serum was revealed regarding frozen storage as well as repeated freeze/thaw cycles. We have added this information as well as references to the method section.
VERSION 1 -AUTHOR RESPONSE
Results
"and there was a very high correlation between hypertension and the intake of heart medications" is this relevant? Response: Indeed, this high correlation between hypertension and the intake of heart medications is not a surprise. However, this shows that the collected data is reasonable. Hence, we left this information in the manuscript. "In a recent study, we were able to demonstrate that a combination of mesothelin and calretinin was able to improve the performance of mesothelin alone (unpublished results)" This is a relevant point which cannot be simply described Response:
In the meantime, the results of the above-mentioned study have been published (Johnen et al.:
Calretinin as a blood-based biomarker for mesothelioma, BMC Cancer 2017;17(1):386). We have now cited this publication in the manuscript.
Reviewer: 2 Reviewer Name: Elisa Giovannetti Institution and Country: VUmc, The Netherlands Please state any competing interests or state "None declared": None declared
Please leave your comments for the authors below. This is an important study showing that mesothelin and calretinin have high specificities in a cohort of cancer-free elderly men, and that calretinin might be a useful adjunct to mesothelin for the early detection of mesothelioma, with an increase of the specificity to 99.1% (95% CI 97.9 -99.7%) for this marker panel. Moroever, the Authors correctly pointed out that mesothelin was strongly affected by renal dysfunction and at a lower degree by hypertension. Calretinin positivity was also affected by renal dysfunctionbut to a lesser extent -and showed no association with hypertension.
Reviewer: 3 Reviewer Name: Romain Harmancey Institution and Country: University of Mississippi Medical Center, United States of America Please state any competing interests or state "None declared": None declared
Please leave your comments for the authors below. This study from Casjens and colleagues aims to determine plasma levels of the two malignant mesothelioma markers mesothelin and calretinin in a population of cancer-free individuals in order to identify confounding factors influencing their concentrations. Study information on potential influencing parameters was gathered from initial and follow-up questionnaires from a prospective populationbased cohort of 579 elderly men. Variables such as age and hypertension were significantly associated with an increase in mesothelin levels, while no influence of these factors could be found on calretinin. Overall specificity for mesothelin and calretinin were each close to 95%, and a combination of both markers improved specificity above 99%, supporting the use of both markers in the detection of malignant mesothelioma.
This is a well-conducted, very informative population-based study which provides support for the combined use of the two blood-based markers mesothelin and calretinin in order to prevent the detection of false positive for malignant mesothelioma in elderly population afflicted of confounding factors such as hypertension and diabetes. A few additional details regarding the study population and methodology employed should be provided. 4-Page 7, first paragraph: Interassay and intraassay coefficients of variation should be provided for both the mesothelin and calretinin blood-based assays. Response: For the mesothelin assay the intra-assay coefficient of variation (CV) was 3.6% and the inter-assay CV 5.7%. For the calretinin assay the intra-assay CV was 6.3% and the inter-assay CV 6.4%. This information has been added to the Methods section.
1-
5-Page 7, line 16: It is mentioned that the cut-off point for positive calretinin values was set at 1.0 ng/mL and above. In a previous study from these authors describing development of the blood-based assay for calretinin, the median calretinin values in patients with malignant mesothelioma was found to be 0.84 ng/mL. The authors should explain why they decided to use a higher cut-off value in the present study. Response: We have chosen a higher calretinin cut-off at 1.0 ng/mL to guarantee high specificities. In the recent publication by Johnen et al (BMC Cancer 2017; 17(1) :386) we detected a median of 1,01 ng/mL in the German mesothelioma patients.
6-Page 12, line 18: Please correct the typo at "non-hypertensive" Response: Thank you very much for this hint. We have corrected the typo.
